Palvella Therapeutics Inc PVLA.OQ PVLA.O is expected to report resultson May 15 for the period ending March 31 2025
LSEG's mean analyst estimate for Palvella Therapeutics Inc is for a loss of $1.21 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 65.4% in the last three months.
Wall Street's median 12-month price target for Palvella Therapeutics Inc is $49.00, above its last closing price of $20.75.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.66 | -0.64 | -2.72 | Missed | -321.7 |
2024 | |||||
| |||||
| -3.70 | ||||
Sep. 30 2023 | -8.80 | -8.80 | 3.20 | Beat | 136.4 |
Jun. 30 2023 | -12.80 | -12.80 | 4.00 | Beat | 131.3 |
Mar. 31 2023 | -10.73 | -11.20 | -14.40 | Missed | -28.6 |
This summary was machine generated May 13 at 14:45 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。